ALS Ice Bucket Challenge Progress
  • Sign up
  • |
  • Login
  • |
  • Find local services
  • |
  • |




The Golden West Chapter to honor Amylyx Pharmaceuticals at
Champions for Cures and Care on Thursday, November 18, 2021

The Golden West Chapter of the ALS Association will proudly honor Amylyx Pharmaceuticals at the 2021 Champions for Cures and Care celebration on Thursday, November 18, 2021. The one-night-only event will be presented in a virtual format and accessible to sponsors and ticket holders worldwide. This inspirational and informative online gala will feature auction, entertainment, celebrity appearances, and presentation of the Golden West Chapter’s Essey Awards to notable members of the ALS community. Named in honor of one of the Chapter’s founding board members, Richard “Dick” Essey, the prestigious Essey Awards are given annually for outstanding efforts in ALS research, care services, public policy initiatives, awareness, and philanthropy.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease, is a fatal, neurodegenerative illness that affects nerve cells in the brain and the spinal cord. The average life expectancy of a person with ALS is two to five years from diagnosis. As the disease progresses, people with ALS lose the ability to walk, move, speak, swallow and, eventually, to breathe– all while the mind and senses continue to function. Those who have served in any branch of the military are at twice the risk of developing ALS. Currently, there is no known cure.

The Golden West Chapter is proud to recognize Amylyx with the 2021 Commitment to Cures Award for their unwavering efforts to champion drug discovery to benefit people with ALS and related diseases and for their development of AMX0035, currently in investigational trials. Their Phase 2 study named CENTAUR, which was partly funded by Ice Bucket Challenge donations, was designed with input from patients, Northeast ALS (NEALS) Consortium, Neurological Research Institute at Massachusetts General, and Barrow Neurological Institute.

In December 2019, the results from the CENTAUR Phase 2 trial of AMX0035 for ALS showed positive results. In June 2021, Amylyx filed a New Drug Submission (NDS) for AMX0035 for the treatment of ALS with Health Canada. On November 2, 2021, Amylyx announced it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for AMX0035 for the treatment of ALS. On November 4, 2021, the company announced the launch of their Phase 3 Study, named PHOENIX, which will be conducted at approximately 65 sites in Europe and the U.S. The trial will enroll approximately 600 participants with clinically definite or clinically probable ALS within 24 months from symptom onset, which expands on the inclusion criteria used in the previous trial.

"Every day at Amylyx, we’re working to turn neurodegenerative diseases from rapidly progressing conditions into ones that can be managed medically,” said Josh Cohen and Justin Klee, Co-CEOs & Co-Founders, Amylyx Pharmaceuticals. “We're working nights and weekends to make this happen as quickly as posssible."

“The Golden West Chapter presents the Essey Commitment to Cures Award to individuals and companies who champion drug discovery and development in the relentless pursuit of treatments and cures for people with ALS and related diseases,” said Fred Fisher, President and CEO, Golden West Chapter. “The leadership and employees of Amylyx are deserving recipients of this award. The company’s unconventional approaches in ALS research and therapy development are inspiring, and their strong partnerships with industry leaders, scientists, doctors, and organizations are encouraging. We look forward to recognizing Amylyx for their expertise, vision, and community partnership as, together, we fight ALS on all fronts.”

The virtual celebration will also honor California State Assemblymember Dr. Joaquin Arambula as the Dean and Kathleen Rasmussen Advocate of the Year Award for his many efforts as a healthcare advocate and integral role in helping the Golden West Chapter to secure multi-year California State public funding to benefit the Chapter's Wraparound Model of Care.

The event will be hosted by Billy Harris, and will feature James Beard Award-winning Chef Nancy Silverton, and musical entertainment by Carlos Calvo, Adam Chester, and Jake Shimabukuro. Proceeds from Champions for Cures and Care will provide funding for the Golden West Chapter’s interdependent mission priorities in care services, public policy, and cutting-edge global research – all of which accelerate the search for effective treatments and cures for ALS. For sponsorship, tickets and more information, please visit or contact Asher Garfinkel, VP of Community Outreach, at or (818) 865-8067 ext 225.


The mission of the Golden West Chapter of The ALS Association is to discover treatments and cures for ALS, and to serve, advocate for, and empower people affected by ALS to live their lives to the fullest. The Golden West Chapter supports people living with ALS and their loved ones in 31 counties throughout California and the state of Hawaii. For more information, visit or on social media @alsagoldenwest.

Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit and follow us on LinkedIn and Twitter.

EVENT DETAILS: Thursday, November 18, 2021 – 9:00 PM EST/ 6:00 PM PST/4:00 PM HST

  • Accessible online worldwide with sponsorship or ticket purchase

  • Event Sponsors include:PhRMA, Biogen, Mitsubishi Tanabe Pharma America, The Essey Family, Rasmussen Foundation, Amylyx Pharmaceuticals, Cedars-Sinai, and Noteware Government Relations.

  • Evening program, with host/auctioneer Billy Harris and Culinary Host Nancy Silverton

  • Live and silent auction; Entertainment featuring Carlos Calvo, Adam Chester, and Jake Shimabukuro

  • Sponsorships, individual tickets and tribute ads still available for purchase at